AIkido Labs

AIkido Labs Inc. (NASDAQ: AIKI) is a pre-revenue, pre-clinical biotech developer focused on aggregating and advancing early-stage therapeutic assets from top-tier universities. Its core strategy involves securing exclusive worldwide licenses to build a pipeline targeting prostate cancer, pancreatic cancer, AML, ALL, and a pan-viral antiviral platform. The company's primary achievements include establishing key partnerships with institutions like the University of Maryland, Baltimore, The University of Texas, and Wake Forest University, and positioning itself in the public markets to fund its asset development through strategic capital raises.

An academic licensing and partnership model focused on in-licensing early-stage, patented small-molecule technologies from universities, supplemented by a specific broad-spectrum antiviral drug platform licensed from the University of Maryland, Baltimore.

AIkido faces intense competition in oncology from large pharma and biotech companies with approved drugs and advanced clinical candidates. In antivirals, it competes with both virus-specific therapies from major players and a handful of other entities pursuing broad-spectrum approaches, though its academic-backed platform is at a significant resource disadvantage.